The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma.
 
Mohammed M. Milhem
Honoraria - Amgen; EMD Serono
Consulting or Advisory Role - Amgen; EMD Serono (I)
Travel, Accommodations, Expenses - Amgen; EMD Serono
 
Hassane M. Zarour
Research Funding - Bristol-Myers Squibb; Merck
 
Nashat Y. Gabrail
No Relationships to Disclose
 
David J. Mauro
Employment - Advaxis; Checkmate Pharmaceuticals
Leadership - Advaxis; Checkmate Pharmaceuticals
Stock and Other Ownership Interests - Advaxis; Checkmate Pharmaceuticals
 
Norman M. Greenberg
Employment - Checkmate Pharmaceuticals
Leadership - Checkmate Pharmaceuticals
Stock and Other Ownership Interests - Checkmate Pharmaceuticals
Consulting or Advisory Role - Checkmate Pharmaceuticals
 
William J. Slichenmyer
Employment - AVEO
Leadership - AVEO
Consulting or Advisory Role - Akebia Therapeutics; Alchemia; Alexion Pharmaceuticals; Alkermes; Array BioPharma; Checkmate Pharmaceuticals; Oncosynergy
 
Arthur M. Krieg
Employment - Checkmate Pharmaceuticals
Leadership - Checkmate Pharmaceuticals
Stock and Other Ownership Interests - Checkmate Pharmaceuticals
Consulting or Advisory Role - Intellia Therapeutics; miRNA Therapeutics; RaNA Therapeutics
Patents, Royalties, Other Intellectual Property - Checkmate Pharmaceuticals; Pfizer